Phase II Study of FR901228 in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer
OBJECTIVES: I. Determine the response of patients with refractory or progressive small cell
or non-small cell lung cancer to FR901228.
II. Determine the ability of FR901228 to mediate apoptosis and target gene induction
relative to tumor histology in these patients.
III. Determine the toxicity of this treatment in these patients.
PROTOCOL OUTLINE: Patients are stratified according to disease histology (small cell lung
cancer vs non-small cell lung cancer).
Patients receive FR901228 IV over 4 hours on days 1 and 7. Treatment repeats every 21 days
in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL:
A total of 18-43 patients (9-21 per arm) will be accrued for this study within 18 months.
Interventional
Primary Purpose: Treatment
David S. Schrump
Study Chair
National Cancer Institute (NCI)
United States: Federal Government
CDR0000068031
NCT00020202
June 2000
Name | Location |
---|---|
Surgery Branch | Bethesda, Maryland 20892 |